VRTX News and Press, Vertex Pharmaceuticals Incorporated

2024-05-12 14:47:00 ET There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity. However, Vertex Pharmaceuticals (NASDAQ: VRTX) , a drugmaker with a monopoly in the cy...

2024-05-12 12:20:00 ET The stock market has taken investors for a wild ride these last few years. When you're investing in stocks for many years, though, even multiple tough market cycles shouldn't deter you from your core investing thesis about quality companies. Even as the S&P ...

2024-05-12 11:22:00 ET This week, the healthcare sector saw 12 companies reporting their quarterly earnings, with 8 of them beating their bottom-line numbers for the quarter.... Read the full article on Seeking Alpha For further details see: 8 out of 12 S&P 500 healthcar...

2024-05-11 06:50:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...

2024-05-10 12:44:07 ET More on Alpine Immune Sciences Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences Vertex To Buy Alpine Immune - Why This Deal Feels Sli...

2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...

2024-05-09 14:10:33 ET More on bluebird bio bluebird bio, Inc. (BLUE) Q4 2023 Earnings Call Transcript bluebird bio Is Priced Below IP Value bluebird bio reports Q1 results bluebird bio Q1 2023 Earnings Preview Seeking Alpha’s Quant Rating on b...

2024-05-09 09:32:14 ET Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Trans...

2024-05-08 05:43:00 ET Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 8% from a peak they reached this January. The price action doesn't jive with the biopharmaceutical company's cash flows and the potential value of the assets it's developing. Following some enc...

2024-05-07 09:01:37 ET Apple ( NASDAQ: AAPL ) recently updated its capital return plan by adding a $110B to its buyback program. According to data highlighted by Mizuho, this massive buyback program is larger than 84% of the stocks that sit inside the S&P 500.... Read ...